Home / Themes / GLP-1 Long '24: GLP1 Drug Producer
GLP-1 Long '24: GLP1 Drug Producer Portfolio (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 4 with notes · 3 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThe current thesis on GLP-1 drug producers in Spring 2025 is bullish, driven by the increasing adoption and market expansion of GLP-1 drugs for various indicati
Thesis
The current thesis on GLP-1 drug producers in Spring 2025 is bullish, driven by the increasing adoption and market expansion of GLP-1 drugs for various indications beyond diabetes, including obesity, NASH, and potentially Alzheimer'Äôs disease. The market dynamics are supported by strong clinical trial outcomes, significant demand from patients, and the development of oral formulations. However, rising competition and potential regulatory challenges pose risks to sustained dominance for existing market leaders.
Bull case
There is strong clinical evidence supporting the efficacy of GLP-1 drugs in treating obesity and other comorbid conditions, which has driven increased adoption and expanded the addressable market.
Oral GLP-1 formulations are in development and expected to significantly increase patient compliance and market penetration.
Ongoing expansion of indications for GLP-1 drugs into areas like NASH and Alzheimer'Äôs disease could further boost market growth and revenue streams.
Bear case
Increased competition from new entrants and alternative therapies could lead to market share erosion for current producers.
Regulatory scrutiny concerning long-term side effects and pricing pressures could impact profitability and market dynamics.
Supply chain constraints, particularly in autoinjector production, may limit the ability to meet rising demand efficiently.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Regulatory approval updates | As occurred | Regulatory landscape and potential market entry timing | Google_Sheets |
| Clinical trial outcomes for new indications | Quarterly | Effectiveness and potential market expansion of GLP-1 drugs | Google_Sheets |
| Prescription trends and sales data | Monthly | Market adoption and revenue growth | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| LLY_f0ee4b85 | upcoming acquisition | 2026-02-04 | 2026-12-31 | Completion of the acquisition of Ventix. | This strategic action will add multiple clinical stage assets to Lilly's pipeline, potentially impacting future growth and investor sentiment. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_e5f65ab8 | in 2026 | 2026-01-01 | 2026-12-31 | Anticipated reduction in Medicaid access for obesity coverage in key states like California. | This could negatively impact volume growth and access for a segment of patients, potentially acting as a drag on revenue. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_ab8f04c3 | Later this year | 2026-07-01 | 2026-12-31 | Results from the Phase 3 pirtobrutinib trial, Bruin CLL322, evaluating pirtobrutinib in previously treated CLL/SLL patients. | Successful results could form the basis for an additional regulatory submission later in the year, expanding the potential market for pirtobrutinib in oncology. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_3bb3949c | the next phase three readout | 2026-02-04 | 2026-12-31 | Phase 3 readout of the 8,000-patient EMBER-4 trial for Imlunestrant in adjuvant breast cancer. | Positive data could establish Imlunestrant as a significant treatment option in early breast cancer, expanding its label and revenue potential for Lilly's oncology portfolio. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_13c4f6ae | expect to initiate new phase three programs | 2026-02-04 | 2026-12-31 | Initiation of new Phase 3 programs for two oncology small molecules: tirsolecimid and vepubratinib. | This advances Lilly's oncology pipeline, potentially leading to new treatment options with improved tolerability and efficacy, supporting long-term growth. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_41973547 | in 2026 | 2026-02-04 | 2026-12-31 | Initiation of several more Phase 2 and Phase 3 trials for brenepatide, including a Phase 3 trial for major depressive disorder. | Expands the potential applications of incretins into neuroscience, opening new large markets and diversifying Lilly's pipeline beyond cardiometabolic health. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_84cbeb5e | later this year after the Achieve IV trial is complete | 2026-07-01 | 2026-12-31 | Completion of the US regulatory submission of Orforglipron for type 2 diabetes. | This submission will expand the potential market for Orforglipron into type 2 diabetes, leveraging its oral formulation for broader patient access and revenue generation. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_9d9c78c8 | in 2026 | 2026-02-04 | 2026-12-31 | Readout of six additional Phase 3 trials for Retatrutide, including the core registration package for TRIUMPH (obesity) and Transcend (type 2 diabetes) programs. | These readouts are crucial for the regulatory submission of Retatrutide, which has shown significant weight loss potential and could become a new treatment option for severe obesity and T2D. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_93c0ffad | in 2026 | 2026-02-04 | 2026-12-31 | Regulatory submission of the Core TRIUMPH program results for Retatrutide for overweight, obesity, obstructive sleep apnea, and osteoarthritis of the knee. | This submission initiates the regulatory process for Retatrutide across multiple indications, paving the way for future approvals and market entry, further strengthening Lilly's incretin portfolio. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_2a06adb9 | in 2026 | 2026-02-04 | 2026-12-31 | Top-line results from the Together PSO trial evaluating Taltz and Zepbound in adults with moderate to severe plaque psoriasis and obesity/overweight. | Positive results could demonstrate additional efficacy of incretin combinations in immunology, expanding the utility and market for both Taltz and Zepbound. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_ada93b14 | as we head into the back end of this year and mostly into 2027 | 2026-07-01 | 2027-12-31 | Increased employer opt-in for commercial coverage of obesity medicines. | Expanded commercial coverage will increase access and reimbursement for obesity medicines, driving volume growth and revenue for the broader market. | Theme | 2026-02-04 | earnings_transcript | LLY (ticker) |
| LLY_5dfbe593 | ongoing effort | 2026-02-04 | 2027-12-31 | Gaining Mounjaro reimbursement in additional international countries for type 2 diabetes. | Successful reimbursement efforts will expand access and drive volume growth for Mounjaro in international markets, contributing to OUS revenue. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |
| AMGN_ce3d8cd2 | Including preparing for Miratide's launch. | 2026-01-01 | 2026-12-31 | Preparations and potential launch of Meritide, a novel therapy for obesity, type 2 diabetes, and related conditions. | Meritide is a key growth driver for Amgen. Its successful launch and market penetration would significantly impact Amgen's revenue and competitive position in the rapidly growing GLP-1 market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_f1821dd7 | We plan to launch TEPEZZA in additional markets in 2026 | 2026-01-01 | 2026-12-31 | Launch of TEPEZZA in additional international markets. | Expanding TEPEZZA's geographic reach will contribute to its global sales growth and further establish Amgen's presence in the thyroid eye disease market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_a4f12076 | 2026 will be a year of disciplined data generation. From a number of exciting phase II and phase III programs that will pave the way for long-term growth at Amgen Inc. | 2026-01-01 | 2026-12-31 | Data generation and potential readouts from multiple ongoing Phase III clinical trials for Meritide in chronic weight management, ASCVD, heart failure, and sleep apnea. | Positive data from these late-stage trials could significantly enhance Amgen's competitive position in the rapidly expanding obesity and cardiometabolic markets, materially impacting future revenue guidance and valuation. Conversely, unfavorable outcomes would represent a significant setback. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_2e8df87c | August 19, 2026 (estimated) | 2026-08-19 | 2026-08-19 | Completion of the Phase III HZNP-DAZ-301 study for Dazodalibep in Sjogren's syndrome with moderate-to-severe systemic disease activity. | This is a key data collection milestone for a potential new treatment for Sjogren's disease, a condition with high unmet medical need, and could lead to future regulatory filings and market expansion. | Ticker | 2026-04-30 | earnings_transcript | AMGN (ticker) |
| AMGN_b978ca77 | 2026-09-07 (Estimated) | 2026-09-07 | 2026-09-07 | Initiation of the Phase 2/3 study (NCT07598825) for UPLIZNA (inebilizumab) in participants with autoimmune hepatitis. | This initiation represents the expansion of UPLIZNA into a new, significant autoimmune indication, broadening its potential therapeutic reach and future revenue streams. | Ticker | 2026-04-30 | earnings_transcript | AMGN (ticker) |
| LLY_cf82d1b5 | a few markets late in 2026 | 2026-10-01 | 2026-12-31 | Launch of Orforglipron in a few international markets (e.g., UAE). | This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration. | Ticker | 2026-02-04 | earnings_transcript | LLY (ticker) |